Consensus Can-Fite BioPharma Ltd. Nyse

Equities

End-of-day quote Nyse Other stock markets 23:00:00 04/02/2024 GMT			5-day change	1st Jan Change
2.02 ^USD	-3.35%		-4.04%	-8.18%

06-10	Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	CI
06-06	Transcript : Can-Fite BioPharma Ltd. - Special Call

ad6fd2.ZWqjVZxTrWDHSUqY8WbbuKyZXA6gbOA1Vs8au-yCbwQ.CBDiCvMX6TGgGSn9lC7s74HsNUnIKadEF7tojN2xF3I0HJQw7wHyDLAgGw~011965984dd3f1b12d87cd79e4c6e721

HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating	24/10/23	MT
CAN FITE BIOPHARMA : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target	24/06/21	MT
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus	16/03/21	MT